Skip to main content
BC Innovations
Feature Story

Hi-fi hybridomas

A hybridoma platform for rapid, uniform antibody expression

A team from ETH Zurich has developed a method for producing high-fidelity hybridomas by using CRISPR-based gene editing, and believes the system can address the unreliability of research antibodies that has fed into the "reproducibility crisis." The result is a faster process and purer yield, according to the group.

Traditionally, hybridoma cells are made by immunizing animals against an antigen, isolating antibody-producing B cells and then individually fusing each of the B cells to a myeloma cell partner to create immortalized cell lines that secrete a single antibody with the relevant specificity.

Read Article

Today's Biotech & Pharma News

  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial